Physician Perspectives 2017: Use of ustekinumab in IBD

Physician Perspectives 2017: Use of ustekinumab in IBD

Summary

This Physician Perspectives survey focuses on the use of ustekinumab in IBD.

UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn's disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.

73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.

Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.

The report includes following topics-

- Current clinical use of UST

- UST safety & efficacy

- UST patient monitoring

- Treatment response to UST

- UST treatment strategies

- Future use in UC.

Scope

- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists

- Physicians interviewed were from 5EU and US countries

- This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.

Reasons to buy

- Qualitative insight from 100 high-prescribing specialists in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.